Unique Association of p53 Mutations with Undifferentiated but not with Differentiated Carcinomas of the Thyroid Gland

Takahsi Ito, Toshio Seyama, Terumi Mizuno, Naohiro Tsuyama, Tomonori Hayashi, Yuzo Hayashi, Kiyohiko Dohi, Nori Nakamura, and Mitoshi Akiyama

Abstract

Thyroid neoplasms show a wide variety of lesions varying from slowly growing differentiated adenocarcinomas to rapidly proliferating undifferentiated carcinomas. There has been some histopathological evidence that the undifferentiated thyroid carcinomas are derived from differentiated carcinomas. Moreover, it is suspected that some genetic events might be associated with such changes. In the present study, mutations in the p53 gene were investigated by direct sequencing analysis after polymerase chain reaction amplification of exons 5 to 8, using paraffin-embedded primary tumors and cultured cells.

No mutations in exons 5 to 8 were detected in 10 differentiated papillary adenocarcinomas, whereas 6 of 7 undifferentiated carcinomas were found to carry base substitution mutations. Sequencing analysis confirmed mutations at codons 135 (TGC -> TGT), 141 (CCC -> CCT), 178 (CAC -> GAC), 213 (CGA -> TGA), 248 (CGG -> CAG, CGG -> TGG), and 273 (CGT -> TGT). The spectrum of mutations (G:C to A:T transitions in 7 of 8) might be a specific feature of the spontaneous cancers. The results strongly suggest that, in human thyroid glands, p53 mutations play a crucial role in the progression of differentiated carcinomas to undifferentiated ones.

Introduction

According to the current concept of carcinogenesis, tumor development consists of multistep accumulations of adverse genetic and epigenetic events (1). These genetic events include activation of dominantly acting oncogenes by point mutations, rearrangements, or amplification and inactivation of tumor suppressor genes via point mutations or deletions. Among the tumor suppressor genes identified, the p53 gene is the best understood and its mutation has been shown to be associated with many types of common cancers, such as colon, lung, liver, esophagus, and breast cancer (2). Interestingly, the majority of such p53 gene mutations are clustered in four hot spot regions (codons 117-1142, 171-181, 235-258, and 270-286) that are highly conserved among different species (3, 4).

In colorectal carcinomas, where the multistep nature of carcinogenesis has been studied in detail, the p53 mutation is suspected to be a late event and relates to the adenoma-carcinoma transition (5). In this regard, thyroid carcinoma also might serve as an interesting model. It has been recognized that most of the thyroid neoplasms are differentiated tumors with high curability, whereas occasional undifferentiated carcinomas kill the host shortly after their diagnosis. Furthermore, it is believed that undifferentiated carcinomas of the thyroid gland mostly arise from well-differentiated tumors (6-9). In thyroid carcinomas, dominantly acting activated oncogenes of ras point mutations and ret translocations have been detected (10, 11), whereas mutations of the p53 gene in thyroid neoplasms have not been investigated. In the present study, we describe a new finding that p53 mutations are uniquely associated with undifferentiated thyroid carcinomas but not with differentiated papillary adenocarcinomas.

Materials and Methods

Ten cases of differentiated papillary adenocarcinoma, six cases of undifferentiated carcinoma, and one cell line 8305C (JCRB 0824) established in our laboratory from an undifferentiated carcinoma of the thyroid were investigated in this study. Tissues derived either from surgical resections or autopsies were fixed with 10% formalin and embedded in paraffin blocks. Five 5-μm-thick sections (9-100 mm2) of each tissue were sufficient for the PCR2 study. Among the five serial sections, the first and fifth ones were stained with hematoxylin and eosin for histological assessment. After microscopic identification, apparent normal portions and tumor portions were collected from the remaining three sections with stainless steel disposable scalpels. Subsequently, they were deparaffinized with 1 ml of xylene, washed with 100% ethanol, and treated in 100 μl of digestion buffer (50 mm Tris-Cl, pH 8.5-1 mm EDTA-0.5% Tween 20) with 100 μg of protease K at 37°C for 48 h. After phenol-chloroform extraction, genomic DNA was precipitated with ethanol. Genomic DNA from cell line 8305C was also prepared by the protease K-phenol chloroform extraction method.

Genomic DNA (200 ng) was subjected to PCR amplification in 20 μl of solution containing 50 mm KCl, 10 mm Tris-Cl (pH 8.3), 5.5 mm MgCl2, and 500 μM concentrations each of four deoxynucleotide triphosphates, 2 pmol of PCR primers, and 0.5 unit of Taq DNA polymerase (Perkin-Elmer Cetus) under 40 cycles of thermal conditions as follows: 30 s at 94°C (denaturation); 1 min at 60°C (annealing); and 30 s at 72°C (polymerization). The products of PCR were purified by low melting agarose gel (3%) electrophoresis. Using 1% of the purified product as templates, 35 cycles of asymmetrical PCR were performed in 20 μl of the same solution described above except with an uneven molar ratio of the two primers (1 pmol:20 pmol). The products of asymmetrical PCR were purified by precipitation with ethanol and isopropyl alcohol in the presence of ammonium acetate. Sequencing primers were labeled on their 5'-ends with [α-32P]ATP and T4 polynucleotide kinase. Purified asymmetrical PCR products were sequenced directly by the dideoxy chain termination method of Sanger et al. (12). Template DNA was denatured at 95°C for 5 min, annealed with 1 pmol of labeled sequencing primer at 65°C for 10 min, and sequenced with Sequenase version 2.0 kit reagents (U. S. Biochemical). Mutations were confirmed in the sequence of sense and antisense strands. The primers used for PCR amplification and direct sequencing of exons 5, 6, 7, and 8 have been described previously (13).

Received 12/4/91; accepted 1/17/92.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 To whom requests for reprints should be addressed.

The abbreviation used is: PCR, polymerase chain reaction.
Results

Direct sequence analysis of p53 gene exons 5 to 8 was performed after PCR amplification in 17 cases of thyroid carcinoma. No mutations could be detected in 10 differentiated papillary adenocarcinomas, whereas base change mutations were detected in 6 of 7 (86%) of the undifferentiated carcinomas, as described in Table 1. Details of the mutations are summarized in Table 2. The base substitution found in the anaplastic cell line 8305C was a C:G to T:A transition at the first base of codon 273 with loss of the wild-type nucleotide at the site of the substitution (Fig. 1).

Mutations in cases 2 and 3 were G:C to A:T transitions at the second base of codon 248, with a wild-type nucleotide band of equal intensity in case 2 and with a weak wild-type nucleotide in case 3 (Fig. 1) at the site of the base substitution. The first base of codon 213 in case 4 was mutated from C:G to T:A with uneven banding pattern (Fig. 1).

Two nonsense mutations and one missense mutation were found in case 5; they were all C:G to T:A with a wild-type nucleotide band of equal intensity (Fig. 1).

Table 2 p53 mutations in undifferentiated carcinomas

<table>
<thead>
<tr>
<th>Case 1</th>
<th>Codon</th>
<th>Nucleotide substitution</th>
<th>Amino acid change</th>
<th>Loss of wild type</th>
<th>Germline mutation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>273</td>
<td>CGT → TGT</td>
<td>Arg → Cys</td>
<td>+</td>
<td>NT</td>
</tr>
<tr>
<td>2</td>
<td>248</td>
<td>CCG → CAG</td>
<td>Arg → Gin</td>
<td>-</td>
<td>NT</td>
</tr>
<tr>
<td>3</td>
<td>248</td>
<td>CCG → CAG</td>
<td>Arg → Gin</td>
<td>-</td>
<td>NT</td>
</tr>
<tr>
<td>4</td>
<td>213</td>
<td>CGA → TGA</td>
<td>Arg → Gin</td>
<td>-</td>
<td>NT</td>
</tr>
<tr>
<td>5</td>
<td>135</td>
<td>TGG → TGT</td>
<td>Nonsense</td>
<td>NS</td>
<td>NT</td>
</tr>
<tr>
<td>6</td>
<td>178</td>
<td>CAC → GAC</td>
<td>His → Asp</td>
<td>+</td>
<td>-</td>
</tr>
</tbody>
</table>

* Numbers in parentheses, percentages of mutations.

Discussion

Mutations of the p53 gene are the most commonly observed genetic alterations in human cancers. However, such mutations have not been investigated previously in thyroid cancers. In the present study, we have found a very strong association of p53 mutations in undifferentiated thyroid carcinomas, but no association in differentiated papillary adenocarcinomas. These mutations, except in one case, were clustered in four regions, which are highly conserved among different species (14). Interestingly, there was only one exceptional mutation that occurred out of the well-conserved regions resulting in a stop codon. In many other human tumors, most of the p53 mutations are localized in these regions and among them there are at least three mutational hot spots affecting codons 175, 248, and 273 (3). The frequency of mutations occurring in each of the hot spot regions and their type of base substitution differs depending on the cancer type. In lung and esophageal cancers related to cigarette smoking, G:C to T:A transversions are the most frequent (2, 15, 16). In hepatocellular carcinoma, related to hepatitis virus infection and ingestion of contaminated food with aflatoxin B1 in China and southern Africa, G:C to T:A transversions at codon 249 are the most frequent gene alteration (13, 17). These findings suggest a close correlation between etiological agents in the environment and specific types of base substitutions.

Unfortunately, there is nothing known about the exogenous risk factors of undifferentiated carcinomas of the thyroid gland. According to the sequential analysis in this study, seven of eight mutations were G:C to A:T transitions, among which three were G:C to A:T transitions at the CpG dinucleotide of codon 248. This base substitution pattern is similar to that of most other cancers such as colon, breast, lung (small cell), and leukemia and might be characteristic of spontaneous mutations in mammalian cells (2).

In the thyroid carcinomas, one-half of the undifferentiated carcinomas showing only a single mutant band on the sequencing gel represent a loss of the normal allele. On the other hand, two cases showed both normal and mutant bands, which might be due to the remaining normal allele of the p53 gene. Considering the retention of the normal allele from these findings, it cannot be excluded that the wild-type allele might be derived from contamination by infiltrating inflammatory cells and stromal cells and that the residual allele might be mutated elsewhere besides exons 5 to 8. However, these data can also suggest the possibility that the single p53 mutation of one allele with a remaining normal allele can be involved in tumor pro-
gression through a dominant negative effect, which might be
mediated by the binding of the mutant p53 product to the wild-
type product (18, 19). Subsequently, during further tumor pro-
gression, another loss of growth control can be exerted when
the wild-type allele is lost (4).

In the thyroid carcinoma it is generally agreed that undiffer-
entiated thyroid carcinomas mainly arise from preexisting dif-
ferentiated carcinomas; this hypothesis is supported by much
clinical and pathological evidence (6–9). Further, p53 mutation
was detected exclusively at the undifferentiated foci in a thyroid
carcinoma where various histological features of normal, differ-
entiated, and undifferentiated carcinomas were observed simulta-
nously.3 The characteristics of slow growth of tumor cells with
no p53 mutations in differentiated carcinomas and rapid
growth of cells with an extremely high frequency of p53 muta-
tions in undifferentiated carcinomas suggest that p53 muta-
tions, which emerged during the growth of differentiated car-
cinomas, might result in undifferentiated carcinomas due to
their uncontrolled growth (18, 19) and dedifferentiation (20).

Acknowledgments

We thank Drs. James E. Trosko, Yukio Takeshima, and Rumi
Haruta for fruitful discussions and encouragement. We are very grateful
to Masumi Enno, Hiromi Tagawa, and Norie Ishii for technical sup-
port. We also thank Michiko Takagi for manuscript preparation and
Michael Edington for his review of the manuscript.

References

1. Pilot, H. C., Goldworthy, T., and Moran, S. The natural history of carci-
nogenesis: implications of experimental carcinogenesis in the genesis of
2. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. p53 mutations
Cleary, K., Bigner, S. H., Davidson, N., Baylin, S., Devilee, P., Glover, T.,
Collins, F. S., Weston, A., Modali, R., Harris, C. C., and Vogelstein, B.
Mutations in the p53 gene occur in diverse human tumour types. Nature
Jessup, J. M., van Tuinen, P., Ledbetter, D. H., Barker, D. F., Nakamura,
White, R., and Vogelstein, B. Chromosome 17 deletions and p53 gene
mutations in colorectal carcinomas. Science (Washington DC), 244: 217–
221, 1990.
6. Rosai, J., and Carcangiu, M. L. Current topics, pathology of thyroid tumors:
Frazell, E. L. Spindle and giant cell metaplasia in papillary carcinoma of the
8. Venkatesh, Y. S. S., Ordonoz, N. G., Schultz, P. N., Hickey, R. C., Goepfert,
H., and Samaan, N. A. Anaplastic carcinoma of the thyroid. A clinicopath-
10. Fusco, A., Greico, M., Santoro, M., Berlingerio, M. T., Pilotti, S., Pierotti,
M. A., Dallas Porta, G., and Vecchid G. A new oncogene in human thyroid
papillary carcinomas and their lymph-nodal metastases. Nature (Lond.), 328:
11. Shi, Y., Zou, M., Schmidt, H., Juhasz, F., Stensky, V., Robb, D., and Farid,
N. R. High rates of ras codon 61 mutation in thyroid tumors in an iodide-
12. Sanger, F., Nicklen, S., and Coulson, A. R. DNA sequencing with chain-
C. C. Mutational hotspot in the p53 gene in human hepatocellular carci-
14. Soussi, T., Caron de Fromentel, C., and May, P. Minireview, structural
aspects of the p53 protein in relation to gene evolution. Oncogene, 5:
15. Hollstein, M. C., Metaclif, R. A., Welsh, J. A., Montesano, R., and Harris,
16. Hollstein, M. C., Perli, L., Mandard, A. M., Welsh, J. A., Montesano, R.,
Metaclif, R. A., Bak, M., and Harris, C. C. Genetic analysis of human
esophageal tumors from two high incidence geographic areas: frequent p53
base substitutions and absence of ras mutations. Cancer Res., 51: 4102–4106,
17. Bressac, B., Kew, M., Wands, J., and Ozturk, M. Selective G to T mutations
of p53 gene in hepatocellular carcinoma from southern Africa. Nature
18. Eliyahu, D., Goldfinger, N., Shaulsky, G., Skuin, Y., Aral-N, Rotter, V., and
19. Roviniski, B., and Benchimol, S. Immortalization of rat embryo fibroblasts
Civin, C. I., Stone, K. D., Woo, T., Ravindranath, Y., and Craig, R. W.
Levels of p53 protein increase with maturation in human hematopoietic cells.

3 Manuscript in preparation.
Unique Association of $p53$ Mutations with Undifferentiated but not with Differentiated Carcinomas of the Thyroid Gland

Takashi Ito, Toshio Seyama, Terumi Mizuno, et al.


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/52/5/1369

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.